{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:05Z","timestamp":1791685325998,"version":"4.3.4"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamaneurol.2019.3988","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:31:03Z","timestamp":1574681463000},"page":"199","source":"Crossref","is-referenced-by-count":206,"title":["Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease"],"prefix":"10.1001","volume":"77","author":[{"given":"Alette M.","family":"Wessels","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre N.","family":"Tariot","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Selzler","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja M.","family":"Bragg","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Landry","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Krull","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnCatherine M.","family":"Downing","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Willis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Mullen","sequence":"additional","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland"},{"name":"Now retired"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barker","sequence":"additional","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schumi","sequence":"additional","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Shering","sequence":"additional","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy R.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Stern","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Center, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[{"name":"G\u00e9rontop\u00f4le, Centre Hospitalier Universitaire de Toulouse, Unit\u00e9s Mixtes de Recherche Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale 1027, Universit\u00e9 Toulouse III\u2013Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[{"name":"Toronto Memory Program, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[{"name":"Re:Cognition Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Research Center and Memory Clinic, Fundaci\u00f3 Alzheimer Centre Educacional, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Barcelona\u2013Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi190094r1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease.","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"noi190094r2","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease.","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"noi190094r3","first-page":"209","article-title":"Pathogenesis of Alzheimer\u2019s disease: molecular and cellular mechanisms [in French].","volume":"62","author":"Govaerts","year":"2007","journal-title":"Rev Med Liege"},{"issue":"7","key":"noi190094r4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","article-title":"Intracellular amyloid-\u00df in Alzheimer\u2019s disease.","volume":"8","author":"LaFerla","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"noi190094r5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer\u2019s disease.","volume":"55","author":"Cebers","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"noi190094r6","first-page":"202","article-title":"Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of Alzheimer\u2019s disease, are related to BACE2 inhibition and confined to epidermis and hair.","volume":"3","author":"Cebers","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"noi190094r7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics.","volume":"50","author":"Eketj\u00e4ll","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"noi190094r8","first-page":"247","article-title":"Development review of the BACE1 inhibitor lanabecestat (AZD3293\/LY3314814).","volume":"4","author":"Sims","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"20","key":"noi190094r10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"noi190094r11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope: the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"noi190094r12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease.","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"noi190094r13","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease: the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"noi190094r14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1532-5415.2004.52303.x","article-title":"Galantamine maintains ability to perform activities of daily living in patients with Alzheimer\u2019s disease.","volume":"52","author":"Galasko","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"noi190094r15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community.","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"issue":"4","key":"noi190094r16","first-page":"227","article-title":"A combined measure of cognition and function for clinical trials: the Integrated Alzheimer\u2019s Disease Rating Scale (iADRS).","volume":"2","author":"Wessels","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"noi190094r17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia.","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"issue":"5","key":"noi190094r18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"noi190094r19","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"noi190094r20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"12","key":"noi190094r21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi190094r22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi190094r23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"noi190094r24","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease.","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"issue":"363","key":"noi190094r26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u00df-amyloid in animal models and in Alzheimer\u2019s disease patients.","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"noi190094r27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jnc.13395","article-title":"Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.","volume":"136","author":"Hu","year":"2016","journal-title":"J Neurochem"},{"issue":"3","key":"noi190094r28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer\u2019s \u00df-secretase, have normal phenotype and abolished \u00df-amyloid generation.","volume":"4","author":"Luo","year":"2001","journal-title":"Nat Neurosci"},{"issue":"459","key":"noi190094r29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5620","article-title":"Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice.","volume":"10","author":"Ou-Yang","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"noi190094r30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41598-017-18388-6","article-title":"Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice.","volume":"8","author":"Meakin","year":"2018","journal-title":"Sci Rep"},{"key":"noi190094r31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neurobiolaging.2016.05.009","article-title":"Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor\u2013treated APP transgenic mice.","volume":"45","author":"Beckmann","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"15","key":"noi190094r32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease.","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"noi190094r9","unstructured":"ClinicalTrials.gov. A Study of Lanabecestat (LY3314814) in Early Alzheimer\u2019s Disease Dementia. NCT02972658. https:\/\/clinicaltrials.gov\/ct2\/results?cond=NCT02972658&term=&cntry=&state=&city=&dist=. Accessed October 11, 2019."},{"key":"noi190094r25","unstructured":"US Food and Drug Administration. Highlights of prescribing information: ILARIS (canakinumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125319s047lbl.pdf. Updated July 2019. Accessed September 17, 2019."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2755347\/jamaneurology_wessels_2019_oi_190094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T11:19:53Z","timestamp":1594639193000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2755347"}},"subtitle":["The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.3988","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}